Search - tctmd.com

Displaying 881 - 900 of 984

Sort: Relevancy | Date

Presentation TCT 2013

Heparin Versus Bivalirudin– In-hospital And 30 Day MACE In Patients Having DES Implantation

Presenter: Evan Shlofmitz, Richard Shlofmitz, Simcha Pollack, Elizabeth Cormier, Elizabeth Haag, Nathaniel Reichek

January 31, 2013

Presentation TCT 2013

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Presenter: Emmanouil Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc Claeys, Jan Cornel, Philip Aylward, Basil Lewis, Douglas Weaver, Gunnar Brandrup- Wognsen, Susanna Stevens, Lars Wallentin, Stefan James

January 31, 2013

Presentation TCT 2013

Ecarin Clotting Time (ECT) more accurately reflects bivalirudin concentration than Activated Clotting Time (ACT) in patients undergoing Percutaneous Coronary Intervention using...

Presenter: Ronan Margey, Helen Ridgway, Richard Rullman, Jeff Spencer, Ronan Margey, Iris McNulty, Aditya Mangla, Sotir Polena, Daniel Soffer, Ik-Kyung Jang

January 31, 2013

Presentation TCT 2013

Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Presenter: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Vassilios Gkizas, George Kassimis, Konstantinos Theodoropoulos, Tsigkas Grigorios, Ioannis Chiladakis, Anastasia Damelou, George Hahalis, Periklis Davlouros

January 31, 2013

Presentation TCT 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Shen, Vicken Aharonian, Prakash Mansukhani, Gregg Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett, Richard Contreras, Somjot Brar

January 31, 2013

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

Presentation TCT 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presenter: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Amro Elnagar, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong

January 31, 2013

Presentation TCT 2013

A Preclinical Comparative Histological Evaluation of the Renal Artery and Nerves in the Human Cadaver and Swine model

Presenter: Radhika Tunstall, Dawn Winsor-Hines, Martin Willard, Barbara Huibregtse

January 31, 2013

News Conference News TCT 2012

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

November 01, 2012

Presentation TCT 2012

Case 2: Patient with Stable Class 3 Angina, Triple-Vessel CAD, and Intermediate Syntax and STS Scores(2)

Presenter: Megan Coylewright

October 26, 2012

Presentation TCT 2012

Case 2: Patient with Stable Class 3 Angina, Triple-Vessel CAD, and Intermediate Syntax and STS Scores

Presenter: Megan Coylewright

October 26, 2012

News Conference News TCT 2012

Future Looks Bright for Stem Cell-Based Myocardial Therapy

October 26, 2012

Presentation TCT 2012

TAVR in a Patient with Severe CAD

Presenter: Haim Danenberg

October 25, 2012

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

News Conference News TCT 2012

Type of Vascular Access Not Linked to Silent Cerebral Infarcts

October 25, 2012

Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington

October 25, 2012

Presentation TCT 2012

Part 1: Oral Anticoagulants

Presenter: Christopher Granger

October 25, 2012

Advertisement

Heparin Versus Bivalirudin– In-hospital And 30 Day MACE In Patients Having DES Implantation

Effect of Ticagrelor on the Outcomes of Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From The PLATelet inhibition and patient Outcomes (PLATO) trial

Ecarin Clotting Time (ECT) more accurately reflects bivalirudin concentration than Activated Clotting Time (ACT) in patients undergoing Percutaneous Coronary Intervention using...

Double (360mg) Loading Dose Of Ticagrelor In Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

A Preclinical Comparative Histological Evaluation of the Renal Artery and Nerves in the Human Cadaver and Swine model

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

Case 2: Patient with Stable Class 3 Angina, Triple-Vessel CAD, and Intermediate Syntax and STS Scores(2)

Case 2: Patient with Stable Class 3 Angina, Triple-Vessel CAD, and Intermediate Syntax and STS Scores

Future Looks Bright for Stem Cell-Based Myocardial Therapy

TAVR in a Patient with Severe CAD

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Type of Vascular Access Not Linked to Silent Cerebral Infarcts

Part 2: Antiplatelet Agents

Part 1: Oral Anticoagulants

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content